标题
Novel drugs targeting the androgen receptor pathway in prostate cancer
作者
关键词
Androgen receptor, Prostate cancer, CYP17, Abiraterone, Enzalutamide
出版物
CANCER AND METASTASIS REVIEWS
Volume 33, Issue 2-3, Pages 567-579
出版商
Springer Nature
发表日期
2014-01-03
DOI
10.1007/s10555-013-9472-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Human Steroid Biosynthesis for the Oncologist
- (2016) Mary Louise Auchus et al. JOURNAL OF INVESTIGATIVE MEDICINE
- Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
- (2013) Y. Loriot et al. ANNALS OF ONCOLOGY
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer
- (2013) Robert H. Bradbury et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and Circulating Tumor Cells in Prostate Cancer
- (2013) M. Shiota et al. CANCER RESEARCH
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- Abstract 3848: Preclinical profile of AZD3514: A small molecule-targeting androgen receptor function with a novel mechanism of action and the potential to treat castration-resistant prostate cancer
- (2012) Sarah A. Loddick et al. CANCER RESEARCH
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
- (2012) J. Richards et al. CANCER RESEARCH
- PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era
- (2012) Sean E. McGuire et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
- (2012) Masuo Yamaoka et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats
- (2012) Takahito Hara et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
- (2012) Christopher J Logothetis et al. LANCET ONCOLOGY
- Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
- (2012) Natasha M. DeVore et al. NATURE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way
- (2012) Sanjay N. Mediwala et al. PROSTATE
- Steroid biosynthesis and prostate cancer
- (2012) Nima Sharifi et al. STEROIDS
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
- (2011) M. S. Darshan et al. CANCER RESEARCH
- The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
- (2011) Walter L. Miller et al. ENDOCRINE REVIEWS
- Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
- (2011) Gerhardt Attard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer
- (2011) Y. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer
- (2011) William K. Oh et al. UROLOGY
- Phase I Dose-Escalation Study of the Novel Antiandrogen BMS-641988 in Patients with Castration-Resistant Prostate Cancer
- (2010) D. Rathkopf et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology
- (2010) Rene Bruno et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E
- (2010) C Andrieu et al. ONCOGENE
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease
- (2009) Michael J. Donovan et al. BJU INTERNATIONAL
- Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
- (2009) Gerhardt Attard et al. CANCER CELL
- Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
- (2009) R. M. Attar et al. CANCER RESEARCH
- Increased Expression of Androgen Receptor Sensitizes Prostate Cancer Cells to Low Levels of Androgens
- (2009) K. K. Waltering et al. CANCER RESEARCH
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Duration of Androgen Suppression in the Treatment of Prostate Cancer
- (2009) Michel Bolla et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Coactivator selective regulation of androgen receptor activity
- (2009) Irina U. Agoulnik et al. STEROIDS
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- A Phase I Study of OGX-011, a 2'-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer
- (2008) K. N. Chi et al. CLINICAL CANCER RESEARCH
- Curcumin Blocks the Activation of Androgen and Interlukin-6 on Prostate-Specific Antigen Expression in Human Prostatic Carcinoma Cells
- (2008) K.-H. Tsui et al. JOURNAL OF ANDROLOGY
- Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro
- (2008) A. Schayowitz et al. MOLECULAR CANCER THERAPEUTICS
- Androgen receptor inactivation contributes to antitumor efficacy of 17 -hydroxylase/17,20-lyase inhibitor 3 -hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
- (2008) T. Vasaitis et al. MOLECULAR CANCER THERAPEUTICS
- CYP17 inhibition as a hormonal strategy for prostate cancer
- (2008) Alison HM Reid et al. Nature clinical practice. Urology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started